As the manufacturer of Diprivan^®,
Fresenius Kabi is the:

Market Leader for a Reason

Recognized Worldwide.
Respected for Innovation.
Track Record of Reliable Supply.

Fresenius Kabi is the U.S. market leader, and we’re committed to meeting Diprivan demand with continuous supply.

Diprivan^®. The Propofol that is recognized worldwide.

#1 Prescribed Propofol
in the U.S.¹
Including the U.S., Fresenius Kabi supplies Propofol in 150+ countries.

Diprivan^®. The Propofol respected for innovation.

Please see Important Safety Information.

Diprivan^®. A track record of reliable supply.

Pharmacies need reliable inventory levels. We are committed to providing a consistent supply for you and your patients.

How the Fresenius Kabi manufacturing process keeps Diprivan production for the U.S. market running smoothly.

From obtaining the raw materials to delivering Diprivan, it can take as much as 6 months to produce a vial.

We begin by sourcing components of the drug and the packaging materials, which include many things like: API (Active Pharmaceutical Ingredient), glass vials, stoppers, labels, shipping materials, and much more.

Next comes production planning: making sure we have everything we need to meet demand for Diprivan. We prepare for bulk production by assessing the ingredients using specific software.

Fresenius Kabi increased Diprivan supply by manufacturing product in multiple facilities to help guard against supply interruptions.

How to order Diprivan

Our exclusive 10 mL Diprivan vial was designed to reduce waste for outpatient procedures.

REFERENCE
1. Data on file.

For U.S. Healthcare Professionals

See Full Prescribing Information

Important Safety Information

CONTRAINDICATIONS
DIPRIVAN is contraindicated in patients with Known hypersensitivity to propofol, egg or soybean.

WARNING AND PRECAUTIONS
Hypersensitivity Reactions: Serious and sometimes fatal reactions.

Microbial Contamination: Strict aseptic technique must be maintained during handling. DIPRIVAN vials are never to be accessed more than once or used on more than one person. Administration should commence promptly and be completed within 12 hours after the vial has been opened. Discard unused drug product. Do not use if contamination is suspected.

Cardiovascular depression: Cases of bradycardia, asystole, and cardiac arrest have been reported. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly.

Read More

ADVERSE REACTIONS

The most common adverse reactions >1% were bradycardia, arrhythmia, tachycardia, hypotension, hypertension, decreased cardiac output, movement, apnea, respiratory acidosis during weaning, rash, pruritus, burning/stinging or pain at injection site, and hyperlipemia.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Opioids, Sedatives or Other Analgesic Agents: May increase the anesthetic/ sedative and cardiorespiratory effects.

Valproate: May lead to increased blood levels of propofol.

INDICATIONS AND USAGE

DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for:

Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age.
Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age.
Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients.
Sedation for Adult Patients in Combination with Regional Anesthesia.
Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients.

Limitations of Use:

DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months.
MAC sedation in the pediatric population is not recommended. DIPRIVAN is not indicated for use in Pediatric ICU sedation.

This Important Safety Information does not include all the information needed to use DIPRIVAN^® (Propofol), Injectable Emulsion, USP safely and effectively. Please see full prescribing information for DIPRIVAN^® (Propofol), Injectable Emulsion, USP. Full prescribing information is also available at www.fresenius-kabi.com/us.